FAMU included among 27 HBCUs that will benefit from a 10-year partnership with international pharmaceutical company Novartis and the Novartis US Foundation to work towards eliminating health disparities among minority groups, especially as pertains to clinical trials.
Along with the 26 other colleges and universities, FAMU will receive a portion of $20 million dollars to aid with education and research.
That breaks down to three-year scholarships of up to $10,000 a year for up to 360 students.
"We certainly have more than enough students who will be in line to participate in this opportunity, but that additional $10,000 can make a tremendous difference with a student who is trying to get to FAMU or a student that's already here," said FAMU president Dr. Larry Robinson.
Over an initial period of ten years, the collaboration will focus on four key areas:
Enable the next generation of Black and African American leaders by creating equitable access to high quality education and professional development for future leaders, in health science, technology and business-related fields.
Support the establishment of Digitally Enabled Clinical Trial Centers of Excellence, managed and led by clinical researchers of color, to build trust, increase diversity and inclusivity in clinical trials, and contribute to improved health outcomes for people of color.
Research and validate existing data standards that drive diagnosis, clinical trial endpoints and population health policy to identify areas for increased inclusivity and ensure accurate data collection and unbiased treatment decisions.
Establish Digitally Enabled Research Centers on the impact of the environment and climate change on health to identify solutions to environmental and climate issues that disproportionately affect communities of color.
They'll distribute funding for the program through the Thurgood Marshall College Fund.